11
Participants
Start Date
November 30, 2009
Primary Completion Date
May 31, 2013
Study Completion Date
May 31, 2013
Fulvestrant
Starting dose of 500 mg through a needle into muscle on Days 1 and 15 of Cycle 1 and on Day 1 of Cycles 2 and beyond. On Day 1 of Cycle 1, injections into 2 different muscles, all other times one injection.
MK-0646
Group 3 or Group 4, receive starting dose of 5 mg/kg by vein on Days 1, 18, 15, and 22 of every cycle.
Dasatinib
Group 2 or Group 4, starting dose of 70 mg (capsules) by mouth daily.
UT MD Anderson Cancer Center, Houston
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
Merck Sharp & Dohme LLC
INDUSTRY
Commonwealth Foundation for Cancer Research
UNKNOWN
M.D. Anderson Cancer Center
OTHER